MERIDIA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Meridia, and what generic alternatives are available?
Meridia is a drug marketed by Abbott and is included in one NDA.
The generic ingredient in MERIDIA is sibutramine hydrochloride. There are six drug master file entries for this compound. Additional details are available on the sibutramine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MERIDIA?
- What are the global sales for MERIDIA?
- What is Average Wholesale Price for MERIDIA?
Summary for MERIDIA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 108 |
| Clinical Trials: | 13 |
| Patent Applications: | 1,928 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | MERIDIA at DailyMed |
Recent Clinical Trials for MERIDIA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AstraZeneca | Phase 4 |
| New York State Psychiatric Institute | Phase 4 |
| Yale University | N/A |
Paragraph IV (Patent) Challenges for MERIDIA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MERIDIA | Capsules | sibutramine hydrochloride | 10 mg and 15 mg | 020632 | 1 | 2009-08-14 |
US Patents and Regulatory Information for MERIDIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-001 | Nov 22, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-002 | Nov 22, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-003 | Nov 22, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MERIDIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-002 | Nov 22, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-002 | Nov 22, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-001 | Nov 22, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MERIDIA
See the table below for patents covering MERIDIA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hungary | 201901 | PROCESS FOR PRODUCING N,N-DIMETHYL-1-(1-)4-CHLORO-PHENYL(-CYCLOBUTYL)-3-METHYL-BUTYL-AMINE-HYDROCHLORIDE-MONOHYDRATE | ⤷ Sign Up |
| Japan | S57181043 | ARYLCYCLOBUTYLAMINE DERIVATIVE AS MEDICINE AND MANUFACTURE | ⤷ Sign Up |
| Austria | A132582 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MERIDIA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0397831 | 01C0052 | France | ⤷ Sign Up | PRODUCT NAME: CHLORHYDRATE DE SIBUTRAMINE MONOHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 23289 DU 20010613; REGISTRATION NO/DATE AT EEC: IKS 54770 DU 19990113 |
| 0397831 | 34/2001 | Austria | ⤷ Sign Up | PRODUCT NAME: SIBUTRAMINHYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-24052, 1-24053 20010423; FIRST REGISTRATION: LI 54770 19990113 |
| 0230742 | 2001C/040 | Belgium | ⤷ Sign Up | PRODUCT NAME: MONOHYDRATE DU CHLORHYDRATE DE N,N-DIMETHYL-1-4-CHLOROPHENYL)CYCLOBUTYL-3-METHYLBUTYLAMINE ET COMPOSITIONS PHARMACEUTIQUES LE CONTENANT; NAT. REGISTRTION NO/DATE: 479 IS 52 F 5 20010425; FIRST REGISTRATION: CH 54770 19990113 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
